A detailed history of Simplex Trading, LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 166,089 shares of ALT stock, worth $1.03 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
166,089
Previous 146,259 13.56%
Holding current value
$1.03 Million
Previous $1.49 Million 25.81%
% of portfolio
0.04%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

BUY
$5.91 - $10.23 $117,195 - $202,860
19,830 Added 13.56%
166,089 $1.1 Million
Q1 2024

Apr 25, 2024

BUY
$8.22 - $13.81 $666,872 - $1.12 Million
81,128 Added 124.56%
146,259 $1.49 Million
Q4 2023

Feb 02, 2024

SELL
$2.14 - $11.62 $8,275 - $44,934
-3,867 Reduced 5.6%
65,131 $732,000
Q3 2023

Nov 01, 2023

BUY
$2.4 - $3.45 $49,588 - $71,283
20,662 Added 42.75%
68,998 $179,000
Q2 2023

Aug 04, 2023

BUY
$3.45 - $5.97 $166,759 - $288,565
48,336 New
48,336 $170,000
Q4 2022

Feb 02, 2023

BUY
$8.74 - $16.45 $776,863 - $1.46 Million
88,886 Added 64.53%
226,629 $3.73 Million
Q3 2022

Nov 04, 2022

BUY
$10.67 - $22.41 $133,172 - $279,699
12,481 Added 9.96%
137,743 $1.76 Million
Q2 2022

Aug 03, 2022

BUY
$3.94 - $11.77 $493,532 - $1.47 Million
125,262 New
125,262 $1.47 Million
Q3 2021

Oct 28, 2021

SELL
$8.43 - $16.81 $58,883 - $117,417
-6,985 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$9.85 - $16.46 $68,802 - $114,973
6,985 New
6,985 $68,000
Q2 2020

Jul 13, 2020

SELL
$2.9 - $10.71 $272 - $1,006
-94 Closed
0 $0
Q1 2020

Apr 29, 2020

BUY
$1.69 - $3.8 $158 - $357
94 New
94 $0

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $304M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.